Skip to main content
Clinical Trials/IRCT20240527061915N1
IRCT20240527061915N1RecruitingPhase 3

Comparing the prophylactic effect of adding magnesium to Metoral in reducing atrial fibrillation after coronary artery bypass graft surgery

Arak University of Medical Sciences0 sites102 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Enrollment
102

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
35 years to 75 years (—)
Sex
All

Inclusion Criteria

  • All CABG candidate patients referred to Amirul Mominin Arak Hospital
  • All patients candidates for elective operations
  • The age of patients between 35-75 years
  • All patients are candidates for CABG only
  • All patients who are operated with that pump
  • All patients with informed consent to participate in this study
  • The average duration of surgery is maximum 7 hours
  • All patients who do not have heart valve repair surgery with CABG
  • ASA?,? patients
  • Patients who are not allergic to Metoral-Magnesium
  • All patients who have acid-base disorders resistant to treatment before surgery

Exclusion Criteria

  • Patients who suffer cardio-respiratory arrest during surgery
  • Patients who do not agree to continue the study or cooperate
  • All CABG candidate patients who require valve repair during surgery
  • All patients who, after the induction of anesthesia, the surgeon decides to perform surgery with the pump OFF
  • All patients who have acid-base disorders resistant to treatment before surgery

Investigators

Similar Trials